Faron CEO Markku Jalkanen Outlines Commercial Ambitions
Executive Summary
The US FDA approves IND application of Faron’s lead Traumakine program for acute respiratory distress syndrome as company prepares for pivotal Phase III data readout this spring. The CEO outlines company’s Traumakine commercialization plans and provides update on its Clevegen ambitions.